QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

$6.53
+0.08 (+1.24%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$6.28
$6.85
50-Day Range
$5.27
$10.09
52-Week Range
$2.46
$10.60
Volume
287,234 shs
Average Volume
708,114 shs
Market Capitalization
$251.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.08
30 days | 90 days | 365 days | Advanced Chart
Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Voyager Therapeutics logo

About Voyager Therapeutics

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
101
Year Founded
N/A

Sales & Book Value

Annual Sales
$37.42 million
Book Value
$1.97 per share

Profitability

Net Income
$-71.20 million
Net Margins
-224.48%
Pretax Margin
-224.48%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,688,000
Market Cap
$251.12 million
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/16/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.37 out of 5 stars

Medical Sector

205th out of 1,423 stocks

Biological Products, Except Diagnostic Industry

29th out of 209 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

Is Voyager Therapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Voyager Therapeutics stock.
View analyst ratings for Voyager Therapeutics
or view top-rated stocks.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Voyager Therapeutics
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.19. Voyager Therapeutics had a negative trailing twelve-month return on equity of 76.83% and a negative net margin of 224.48%.
View Voyager Therapeutics' earnings history
.

What price target have analysts set for VYGR?

4 equities research analysts have issued 1 year price objectives for Voyager Therapeutics' shares. Their forecasts range from $6.00 to $45.00. On average, they anticipate Voyager Therapeutics' share price to reach $15.00 in the next year. This suggests a possible upside of 129.7% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Voyager Therapeutics' key executives?
Voyager Therapeutics' management team includes the following people:
  • Dr. Glenn F. Pierce M.D., Ph.D., Independent Director, Interim Chief Scientific Officer & Chief Medical Officer (Age 66, Pay $51.5k)
  • Mr. Robert W. Hesslein, Sr. VP & Gen. Counsel (Age 69, Pay $580.65k)
  • Mr. G. Andre Turenne, Advisor (Age 48, Pay $873.48k)
  • Dr. Steven M. Paul M.D., Exec. Science Advisor & Director (Age 71, Pay $44k)
  • Dr. Alfred W. Sandrock Jr., M.D., Ph.D., Pres, CEO & Director (Age 64)
  • Dr. Krystof Bankiewicz M.D., Ph.D., Founder
  • Dr. Guangping Gao Ph.D., Founder
  • Dr. Mark A. Kay M.D., Ph.D., Founder (Age 63)
  • Dr. Phillip D. Zamore, Founder
  • Ms. Julie Burek, Principal Financial & Accounting Officer (Age 48) (LinkedIn Profile)
What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.01%), BlackRock Inc. (1.34%), JPMorgan Chase & Co. (0.91%), Acadian Asset Management LLC (0.64%), Connor Clark & Lunn Investment Management Ltd. (0.35%) and Goldman Sachs Group Inc. (0.30%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Julie Burek, Omar Khwaja, Robert W Hesslein and Robin Swartz.
View institutional ownership trends for Voyager Therapeutics
.

Which institutional investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, JPMorgan Chase & Co., Vanguard Group Inc., Connor Clark & Lunn Investment Management Ltd., Raymond James Financial Services Advisors Inc., UBS Group AG, and Koss Olinger Consulting LLC. Company insiders that have sold Voyager Therapeutics company stock in the last year include Julie Burek, Omar Khwaja, Robert W Hesslein, and Robin Swartz.
View insider buying and selling activity for Voyager Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., BlackRock Inc., Citigroup Inc., Charles Schwab Investment Management Inc., Group One Trading L.P., Lazard Asset Management LLC, Cutler Group LP, and State Street Corp.
View insider buying and selling activity for Voyager Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $6.53.

How much money does Voyager Therapeutics make?

Voyager Therapeutics has a market capitalization of $251.12 million and generates $37.42 million in revenue each year. The company earns $-71.20 million in net income (profit) each year or ($1.880010) on an earnings per share basis.

How many employees does Voyager Therapeutics have?

Voyager Therapeutics employs 101 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-5340 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.